BCRX 241220 7.00C (BCRX241220C7000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

BCRX241220C7000

Watchlist

0.67
+0.15+28.85%

15min DelayClose Nov 27 16:00 ET

0.67High0.67Low

Intraday

5D
Daily

News

Bullish BioCryst Pharmaceuticals Insiders Loaded Up On US$1.05m Of Stock
Simply Wall StNov 27 08:35 ET
BioCryst Pharmaceuticals' Hereditary Angioedema Drug Gets Recommendation From Ireland Regulator
MT NewswiresNov 18 03:48 ET
BioCryst Launches ORLADEYO (Berotralstat) in Ireland
GlobeNewswireNov 18 02:00 ET
BofA Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating
Moomoo NewsNov 14 10:31 ET · Ratings
BioCryst (BCRX) Receives a Buy From Bank of America Securities
TipRanksNov 14 09:45 ET
When Will BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Become Profitable?
Simply Wall StNov 6 07:23 ET

Comments

Jaguar8

Nov 7 09:30

13G

$BioCryst Pharmaceuticals (BCRX.US)$
BioCryst Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(9.81%)

frogoracletrading

Nov 4 06:06

$BCRX Support / Resistance Levels

Here are the levels to watch this week.
Larger Image: tradingview.com...
$BioCryst Pharmaceuticals (BCRX.US)$

Trytosaveabit

Oct 14 06:13

Update

$BioCryst Pharmaceuticals (BCRX.US)$ BioCryst's ORLADEYO Reduces Hospital Visits and Emergency Care for Hereditary Angioedema Patients, Study Shows
Benzinga· 3 mins ago
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on the use of oral, once-daily ORLADEYO (berotralstat) demonstrating that patients with hereditary angioedema (HAE) in the United States experience significant reductions in healthcare resource utilization (HRU), including significant reduc...

Trytosaveabit

Sep 30 06:02

News

$BioCryst Pharmaceuticals (BCRX.US)$ Reuters
Just
U.S. Government Awards BioCryst $69 Million Rapivab® (Peramivir Injection) Contract for Strategic National Stockpile

Analysts Notebook

Sep 5 06:06

Columns 'Trump Trade' vs. 'Harris Trade': How They Could Shape Your Portfolio

The 2024 U.S. presidential race between former President Donald Trump and current Vice President Kamala Harris is still "incredibly close," according to the latest New York Times survey. As investors await the outcome of the November election, equity analysts are busy parsing through the candidates' pronouncements for clues on which stocks could benefit from their policies.
Jefferies analysts cited 10 possible policies that Tr...

Trump trade: Bitcoin hit record highs and Tesla hits $1 trillion market cap